IPA250117P7500
- 0.00
- 0.000.00%
ImmunoPrecise Antibodies Newsroom
Benchmark Co. Maintains ImmunoPrecise Antibodies(IPA.US) With Buy Rating, Maintains Target Price $3
Benchmark Co. Maintains ImmunoPrecise Antibodies(IPA.US) With Buy Rating, Maintains Target Price $3
Analysts Offer Insights on Healthcare Companies: ImmunoPrecise Antibodies (IPA), Neurocrine (NBIX) and Becton Dickinson (BDX)
ImmunoPrecise Antibodies Is Maintained at Buy by HC Wainwright & Co.
ImmunoPrecise Antibodies Analyst Ratings
ImmunoPrecise Antibodies Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
ImmunoPrecise Antibodies Analyst Ratings
Maintained Buy Rating for ImmunoPrecise Antibodies on Strong Revenue and Strategic Growth Prospects
Benchmark Co. Maintains ImmunoPrecise Antibodies(IPA.US) With Buy Rating, Cuts Target Price to $3
Benchmark Maintains Speculative Buy on ImmunoPrecise Antibodies, Lowers Price Target to $3
ImmunoPrecise Antibodies Analyst Ratings
ImmunoPrecise Antibodies Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
ImmunoPrecise Antibodies Analyst Ratings
HC Wainwright & Co. Reiterates Buy on ImmunoPrecise Antibodies, Maintains $9 Price Target
ImmunoPrecise Antibodies Analyst Ratings
HC Wainwright & Co. Reiterates Buy on ImmunoPrecise Antibodies, Maintains $9 Price Target
Buy Rating Affirmed: ImmunoPrecise Antibodies' Growth and Innovation Drive Positive Outlook
HC Wainwright & Co. Reiterates Buy on ImmunoPrecise Antibodies, Maintains $9 Price Target
ImmunoPrecise Antibodies Analyst Ratings
ImmunoPrecise Antibodies (IPA) Receives a Buy From H.C. Wainwright